TABLE 2.
Challenge route | Organ | Placebo | Treated-relapsed | Significance between placebo and relapsed groups | Significance between placebo controls of each challenge route |
---|---|---|---|---|---|
Inhalation | Liver | 5.5 (4.3 to6.7) | 6.6 (6.0 to7.3) | ns | ns |
Spleen | 6.8 (6.1 to7.6) | 7.6 (7.0 to8.2) | ns | ns | |
Kidney | 4.0 (2.9 to5.1) | 5.3 (4.8 to5.9) | P = 0.0203 | P = 0.0199 between inhalation and ingestion | |
Lung | 7.1 (6.1 to 8.0) | 6.1 (5.6 to 6.8) | ns | P = 0.007 between inhalation and ingestion | |
Blood | 3.3 (2.3 to 4.3) | 4.4 (3.7 to 5.1) | P = 0.0479 | P = 0.015 between inhalation and ingestion | |
P = 0.0179 between inhalation and subcutaneous | |||||
Subcutaneous | Liver | 6.5 (5.6 to 7.5) | 6.4 (5.2 to 7.5) | ns | |
Spleen | 7.5 (7.0 to 7.9) | 7.7 (7.7 to 7.8) | ns | ||
Kidney | 5.1 (4.4 to 5.7) | 5.3 (3.8 to 6.8) | ns | ||
Lung | 6.0 (5.4 to 6.6) | 5.9 (5.4 to 6.3) | ns | ||
Blood | 4.9 (4.2 to 5.6) | 4.4 (3.3 to 5.5) | ns | ||
Ingestion | Liver | 6.4 (5.8 to 7.1) | 6.9 | n/a | |
Spleen | 6.8 (5.8 to 7.9) | 7 | n/a | ||
Kidney | 5.6 (4.6 to 6.6) | 5.6 | n/a | ||
Lung | 5.7 (5.2 to 6.2) | 6.2 | n/a | ||
Blood | 4.5 (4.3 to 4.8) | 3.9 | n/a |
Bacterial load data are presented as log transformation of the number of CFU (CFU present with 95% confidence intervals). ns indicates nonsignificance, and n/a is not applicable due to there only being 1 animal that relapsed following ingestion challenge.